Sort
4,870 grants matching “glp 1”
Preclinical Development of Oxy200 for the Treatment of Osteoporosis
$975,009Frank Stappenbeck · Max Biopharma, Inc. · R44 · FY2018 · AG
Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases
$974,853Jay L Rothstein · Immunext, Inc. · R44 · FY2022 · AI
Novel Adipose Targeted Gene Therapy for Lipodystrophy
$974,604Al Hawkins · Zvelt Therapeutics Inc. · R42 · FY2025 · DK
Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci
$974,575Terry Roemer · Prokaryotics, Inc. · R44 · FY2024 · AI
Preclinical and Clinical Development of Treatment for X-linked Retinoschisis
$973,846Ronald A Bush · National Institute On Deafness And Other Communication Disorders · ZIA · FY2018 · DC
A Novel Engineered Probiotic for the Prevention of Clostridium Difficile Infection
$973,438Gary Fanger · Rise Therapeutics, Llc · R44 · FY2022 · AI
Development of patented tricyclic pyrones molecules for the treatment of Alzheimerâs Disease
$973,076Xinmin Simon Xie · Afasci, Inc. · R44 · FY2017 · AG
Glial Progenitor Cells for Treatment of ALS
$972,329Nicholas J Maragakis · Johns Hopkins University · U01 · FY2010 · NS
A Novel Probiotic for the Treatment of Sjogren's Syndrome
$972,063Gary Fanger · Rise Therapeutics, Llc · SB1 · FY2022 · DE
Neuroprotective role of GLP-1 receptor agonists
$971,839Nigel H. Greig · National Institute On Aging · ZIA · FY2021 · AG
Candidate selection of a LPAR1 antagonist for therapeutic application in NASH
$971,732Fabio Cohen Tucci · Epigen Biosciences, Inc. · R44 · FY2023 · DK
Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis
$970,147Aaron Richard McCabe · Minnetronix, Inc. · R42 · FY2019 · AI
Isovolumetric Multimodal Venous Thrombectomy System
$969,525Stacey Liekweg · Caeli Vascular, Llc · R42 · FY2022 · HL
Novel targeted Chemotherapeutics for Gliobastoma
$968,230Kerry Jean Koller · Quadriga Biosciences, Inc. · R44 · FY2018 · CA
Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia
$968,007Lawrence Paul Wennogle · Intra-Cellular Therapies, Inc. · R44 · FY2008 · MH
CMC of Peptide Formulation for the Treatment of ARDS
$967,740Gerardo M. Castillo · Pharmain Corporation · R44 · FY2023 · HL
A novel vaccine against multidrug-resistant gonorrhea
$967,287Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2019 · AI
Hybrid Molecules Designed to Enhance Antibiotic Activity
$967,036George E Wright · Glsynthesis, Inc. · R44 · FY2008 · AI
Incretin Microdosing for Cardiometabolic Health in People With HIV: The REINFORCE Trial
$966,521Jordan E Lake · University Of Texas Hlth Sci Ctr Houston · R01 · FY2025 · DK
Pre-Clinical HPV16 Antiviral Compound Development
$965,617Christopher Fisher · Nanovir, Llc. · R42 · FY2010 · AI
Universal room temperature stable influenza nanovaccine
$965,238Balaji Narasimhan · Iowa State University · R01 · FY2023 · AI
Clinical Development of Hemostatic Agent ClotFoam for Severe Hemorrhage
$965,052Maja Nowakowski · Biomedica Management Corporation · R44 · FY2012 · HL
Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia
$964,601Lawrence Paul Wennogle · Intra-Cellular Therapies, Inc. · R44 · FY2010 · MH
Preclinical and Clinical Development of Treatment for X-linked Retinoschisis
$964,570Paul Sieving · National Institute On Deafness And Other Communication Disorders · ZIA · FY2019 · DC
Pharmaceutical development of longer-lasting brimonidine eye drops
$964,469Tung Heng Hsueh · Novus Vision Llc · R44 · FY2024 · EY